Literature DB >> 30099497

Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.

K Kunimasa1, H Nakamura2, K Sakai3, M Kimura4, T Inoue4, M Tamiya4, K Nishino4, T Kumagai4, S Nakatsuka2, H Endo5, M Inoue6, K Nishio3, F Imamura4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30099497     DOI： 10.1093/annonc/mdy312

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?

Authors:  Francesca Casaluce; Cesare Gridelli
Journal:  Transl Lung Cancer Res       Date:  2018-12

2.  Genome analysis of peeling archival cytology samples detects driver mutations in lung cancer.

Authors:  Kei Kunimasa; Yosuke Hirotsu; Kenji Amemiya; Yuki Nagakubo; Taichiro Goto; Yoshihiro Miyashita; Yumiko Kakizaki; Toshiharu Tsutsui; Sotaro Otake; Hiroaki Kobayashi; Rumi Higuchi; Kie Inomata; Takashi Kumagai; Hitoshi Mochizuki; Harumi Nakamura; Shin-Ichi Nakatsuka; Kazumi Nishino; Fumio Imamura; Toru Kumagai; Toshio Oyama; Masao Omata
Journal:  Cancer Med       Date:  2020-04-29       Impact factor: 4.452

3.  Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study.

Authors:  Akihiro Yoshimura; Tadaaki Yamada; Yusuke Okuma; Akito Fukuda; Satoshi Watanabe; Naoya Nishioka; Takayuki Takeda; Yusuke Chihara; Shinnosuke Takemoto; Taishi Harada; Osamu Hiranuma; Yukina Shirai; Akihiro Nishiyama; Seiji Yano; Yasuhiro Goto; Shinsuke Shiotsu; Kei Kunimasa; Yoshie Morimoto; Masahiro Iwasaku; Yoshiko Kaneko; Junji Uchino; Hirotsugu Kenmotsu; Toshiaki Takahashi; Koichi Takayama
Journal:  Transl Lung Cancer Res       Date:  2021-08

4.  Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy.

Authors:  Wei Jin; Xin Wang; Jie Wang; Lin Lin
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 6.244

5.  A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.

Authors:  Benjamin C Creelan; Tammie C Yeh; Sang-We Kim; Naoyuki Nogami; Dong-Wan Kim; Laura Q M Chow; Shintaro Kanda; Rosemary Taylor; Weifeng Tang; Mei Tang; Helen K Angell; Martine P Roudier; Marcelo Marotti; Don L Gibbons
Journal:  Br J Cancer       Date:  2020-10-05       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.